Swiss National Bank
XENE icon

Swiss National Bank’s Xenon Pharmaceuticals XENE Stock Holding History

Swiss National Bank’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.82M Buy
162,700
+5,000
+3% +$278K 0.01% 1032
2026
Q1 		$9.17M Buy
157,700
+43,700
+38% +$2.01M 0.01% 1001
2025
Q4 		$5.11M Sell
114,000
-12,400
-10% -$521K ﹤0.01% 1338
2025
Q3 		$5.07M Buy
126,400
+2,100
+2% +$74K ﹤0.01% 1323
2025
Q2 		$3.89M Sell
124,300
-1,300
-1% -$42.4K ﹤0.01% 1430
2025
Q1 		$4.21M Sell
125,600
-1,000
-0.8% -$38K ﹤0.01% 1355
2024
Q4 		$4.96M Buy
126,600
+1,300
+1% +$53.7K ﹤0.01% 1342
2024
Q3 		$4.93M Sell
125,300
-800
-0.6% -$32.3K ﹤0.01% 1334
2024
Q2 		$4.92M Buy
126,100
+2,300
+2% +$91.9K ﹤0.01% 1294
2024
Q1 		$5.33M Hold
123,800
– – ﹤0.01% 1263
2023
Q4 		$5.7M Buy
123,800
+12,100
+11% +$428K ﹤0.01% 1214
2023
Q3 		$3.82M Buy
111,700
+1,900
+2% +$71.1K ﹤0.01% 1443
2023
Q2 		$4.23M Buy
109,800
+8,500
+8% +$338K ﹤0.01% 1413
2023
Q1 		$3.63M Sell
101,300
-11,400
-10% -$421K ﹤0.01% 1455
2022
Q4 		$4.44M Buy
112,700
+4,300
+4% +$157K ﹤0.01% 1388
2022
Q3 		$3.91M Buy
108,400
+600
+0.6% +$21.6K ﹤0.01% 1424
2022
Q2 		$3.28M Buy
107,800
+10,300
+11% +$312K ﹤0.01% 1585
2022
Q1 		$2.98M Buy
97,500
+10,100
+12% +$302K ﹤0.01% 1788
2021
Q4 		$2.73M Buy
87,400
+24,000
+38% +$717K ﹤0.01% 1847
2021
Q3 		$969K Buy
63,400
+1,500
+2% +$26.1K ﹤0.01% 2450
2021
Q2 		$1.15M Sell
61,900
-2,100
-3% -$38.7K ﹤0.01% 2423
2021
Q1 		$1.15M Buy
64,000
+1,500
+2% +$25.4K ﹤0.01% 2295
2020
Q4 		$961K Hold
62,500
– – ﹤0.01% 2308
2020
Q3 		$692K Hold
62,500
– – ﹤0.01% 2270
2020
Q2 		$784K Buy
+62,500
New +$795K ﹤0.01% 2240

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Swiss National Bank's XENE Position: Q2 2026 in Review

Swiss National Bank increased its Xenon Pharmaceuticals (XENE) stake by 3.2% in Q2 2026, buying an estimated $278K and bringing the position to 162,700 shares worth $9.82M. The position accounts for 0.01% of the portfolio, ranked #1032.

Swiss National Bank first reported a position in XENE in Q2 2020 and has held it in 25 quarters since. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Swiss National Bank held 162,700 shares of Xenon Pharmaceuticals worth $9.82M as of Q2 2026.
  • Swiss National Bank bought 5,000 Xenon Pharmaceuticals shares in Q2 2026, an estimated $278K.
  • Xenon Pharmaceuticals made up 0.01% of Swiss National Bank's portfolio in Q2 2026, its #1032 holding.
  • Swiss National Bank first reported a position in Xenon Pharmaceuticals in Q2 2020 and has held it in 25 quarters since.
  • 315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Swiss National Bank's 13F filing for Q2 2026, filed 11 Aug 2026.